Evvy, a women’s health company focused on vaginal microbiome testing and research, has raised a $40 million Series B led by Catalio Capital Management. The funding marks a notable moment for a sector that has long argued it is underfunded, under-researched, and overdue for better data.
The company announced the raise Tuesday, positioning the new capital as fuel for its broader push to improve women’s health insights through vaginal microbiome data. For consumers, clinicians, and investors watching the health tech space, the deal signals growing interest in diagnostics that look beyond traditional testing models.
Evvy Series B funding puts vaginal microbiome data in the spotlight
Evvy’s core focus is the vaginal microbiome: the community of bacteria and other microorganisms that can play a role in reproductive and gynecological health. While microbiome science has gained plenty of attention in gut health, the vaginal microbiome has historically received far less mainstream investment and research support.
That gap is exactly where Evvy has built its brand. By collecting and analyzing microbiome data, the company aims to help build a more detailed picture of conditions and symptoms that many women experience but often struggle to get clear answers for through conventional care pathways.
The new Series B round gives Evvy additional resources to scale its work, strengthen its research efforts, and continue building around a category that sits at the intersection of women’s health, diagnostics, biotechnology, and consumer health tech.
Why Evvy’s $40 million raise matters for women’s health tech
Women’s health startups have been gaining more attention from venture investors, but funding remains uneven compared with other areas of healthcare innovation. Evvy’s $40 million raise stands out because it focuses on a highly specific, data-rich area of health that has often been overlooked in clinical research.
Better vaginal microbiome data could support more informed conversations between patients and providers, especially around recurring symptoms, infections, fertility-related questions, and broader reproductive health concerns. While no single dataset can solve every challenge in women’s healthcare, Evvy’s approach reflects a wider shift toward personalized diagnostics and evidence-based care.
For investors, the company also represents a larger trend: health tech businesses are increasingly being built around proprietary datasets. In areas where research has historically been limited, those datasets can become especially valuable, both for care delivery and for future scientific discovery.
Catalio Capital Management leads Evvy’s Series B round
The Series B was led by Catalio Capital Management, a firm known for backing companies across healthcare, biotechnology, and life sciences. Its involvement adds institutional weight to Evvy’s next phase, particularly as the company looks to deepen its research capabilities and expand its role in women’s health innovation.
The announcement also arrives during a period when investors are becoming more selective about digital health companies. Startups now face pressure to show not just consumer demand, but also clinical relevance, defensible technology, and a believable path to scale. Evvy’s emphasis on microbiome data gives it a distinct position in that competitive landscape.
The future of vaginal microbiome testing and research
Evvy’s funding is not just a startup milestone; it is part of a wider conversation about how women’s health research is funded and prioritized. For decades, many symptoms and conditions affecting women have been minimized, misunderstood, or studied too narrowly. Companies like Evvy are betting that better data can help change that.
The next test will be execution. As Evvy grows, the company will need to keep building trust with consumers, researchers, and clinicians while proving that its microbiome insights can translate into meaningful health outcomes. That is a high bar, but the new funding gives the company more room to pursue it.
With $40 million in fresh capital and Catalio leading the round, Evvy is now one of the more closely watched names in women’s health tech. Its progress could help shape how the industry thinks about vaginal microbiome testing, patient-centered diagnostics, and the future of data-driven reproductive health research.
Tags: #Evvy #WomensHealthTech #VaginalMicrobiome #HealthTech #FemTech
About the Author
